語系:
繁體中文
English
日文
簡体中文
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Lung cancer and personalized medicin...
~
Ahmad, Aamir.
Lung cancer and personalized medicine[electronic resource] :current knowledge and therapies /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
杜威分類號:
616.9942406
書名/作者:
Lung cancer and personalized medicine : current knowledge and therapies // edited by Aamir Ahmad, Shirish Gadgeel.
其他作者:
Ahmad, Aamir.
出版者:
Cham : : Springer International Publishing :, 2016.
面頁冊數:
xiii, 228 p. : : ill., digital ;; 24 cm.
Contained By:
Springer eBooks
標題:
Lungs - Cancer
標題:
Personalized medicine.
標題:
Biomedicine.
標題:
Cancer Research.
標題:
Molecular Medicine.
標題:
Internal Medicine.
標題:
Oncology.
ISBN:
9783319242231
ISBN:
9783319242217
內容註:
1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.
摘要、提要註:
This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer--statistics and epidemiology of lung cancer--along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer--immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
電子資源:
http://dx.doi.org/10.1007/978-3-319-24223-1
Lung cancer and personalized medicine[electronic resource] :current knowledge and therapies /
Lung cancer and personalized medicine
current knowledge and therapies /[electronic resource] :edited by Aamir Ahmad, Shirish Gadgeel. - Cham :Springer International Publishing :2016. - xiii, 228 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.8930065-2598 ;. - Advances in experimental medicine and biology ;946..
1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.
This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer--statistics and epidemiology of lung cancer--along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer--immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
ISBN: 9783319242231
Standard No.: 10.1007/978-3-319-24223-1doiSubjects--Topical Terms:
447997
Lungs
--Cancer
LC Class. No.: RC280.L8
Dewey Class. No.: 616.9942406
Lung cancer and personalized medicine[electronic resource] :current knowledge and therapies /
LDR
:02535nam a2200325 a 4500
001
455464
003
DE-He213
005
20160802153656.0
006
m d
007
cr nn 008maaau
008
161227s2016 gw s 0 eng d
020
$a
9783319242231
$q
(electronic bk.)
020
$a
9783319242217
$q
(paper)
024
7
$a
10.1007/978-3-319-24223-1
$2
doi
035
$a
978-3-319-24223-1
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC280.L8
072
7
$a
MJCL
$2
bicssc
072
7
$a
MED062000
$2
bisacsh
082
0 4
$a
616.9942406
$2
23
090
$a
RC280.L8
$b
L963 2016
245
0 0
$a
Lung cancer and personalized medicine
$h
[electronic resource] :
$b
current knowledge and therapies /
$c
edited by Aamir Ahmad, Shirish Gadgeel.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2016.
300
$a
xiii, 228 p. :
$b
ill., digital ;
$c
24 cm.
490
1
$a
Advances in experimental medicine and biology,
$x
0065-2598 ;
$v
v.893
505
0
$a
1 Lung Cancer Statistics -- 2 Epidemiology of Lung Cancer -- 3 Lung Cancer In Never Smokers -- 4 Immune Therapy -- 5 Anti-angiogenesis in personalized therapy of lung cancer -- 6 Target therapy in Lung Cancer -- 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: an update -- 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy -- 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer -- 10 Chemotherapy Resistance in Lung Cancer -- 11 Current state of metal-based drugs for the efficient therapy of lung cancers and lung metastases.
520
$a
This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer--statistics and epidemiology of lung cancer--along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer--immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
650
0
$a
Lungs
$x
Cancer
$x
Treatment.
$3
447997
650
0
$a
Personalized medicine.
$3
606514
650
1 4
$a
Biomedicine.
$3
463454
650
2 4
$a
Cancer Research.
$3
463530
650
2 4
$a
Molecular Medicine.
$3
463625
650
2 4
$a
Internal Medicine.
$3
341979
650
2 4
$a
Oncology.
$3
205017
700
1
$a
Ahmad, Aamir.
$3
652251
700
1
$a
Gadgeel, Shirish.
$3
653875
710
2
$a
SpringerLink (Online service)
$3
463450
773
0
$t
Springer eBooks
830
0
$a
Advances in experimental medicine and biology ;
$v
946.
$3
463635
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-24223-1
950
$a
Biomedical and Life Sciences (Springer-11642)
筆 0 讀者評論
多媒體
多媒體檔案
http://dx.doi.org/10.1007/978-3-319-24223-1
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入